Targets › S1PR1
10 programs from 9 companies in 26 trials: 11 Phase 3, 10 Phase 2, 4 Phase 4, 1 Phase 1; Immunology, Neurology, Oncology; next expected readout Dec 2026.
G protein-coupled receptor for the bioactive lysosphingolipid sphingosine 1-phosphate (S1P) that seems to be coupled to the G(i) subclass of heteromeric G proteins. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. (UniProt, P21453)
Open in Phaseline: the race on S1PR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Fingolimod Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | S1PR5, S1PR2, S1PR4, S1PR3, S1PR1 | Phase 4 | Multiple Sclerosis; Diabetes Mellitus, Type 2; Non Small Cell Lung Cancer | Sep 2027 |
| Bristol-Myers Squibb | Ozanimod Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor 5 modulator | S1PR1, S1PR5 | Phase 4 | Relapsing Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Colitis, Ulcerative; Alzheimer Disease | Dec 2028 |
| Viatris Innovation | Cenerimod Sphingosine 1-phosphate receptor Edg-1 modulator | S1PR1 | Phase 3 | Lupus Erythematosus, Systemic; Nephritis, Lupus | Dec 2026 |
| Priothera SAS | mocravimod Sphingosine 1-phosphate receptor Edg-1 agonist | S1PR1 | Phase 3 | Adult Acute Myeloid Leukemia | May 2027 |
| Boehringer Ingelheim | BI 764198 Sphingosine-1-phosphate receptor modulator | S1PR1 | Phase 3 | Focal Segmental Glomerulosclerosis; Proteinuric Kidney Diseases | Jan 2028 |
| Vanda Pharmaceuticals | Ponesimod Sphingosine 1-phosphate receptor Edg-1 agonist | S1PR1 | Phase 3 | Moderate-to-severe Chronic Plaque Psoriasis; Ulcerative Colitis (UC) | Aug 2028 |
| Pfizer | Etrasimod Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator | S1PR1, S1PR4, S1PR5 | Phase 3 | Ulcerative Colitis; Colitis, Ulcerative; Healthy Participant; Pouchitis | Jun 2029 |
| Novartis | Siponimod Sphingosine 1-phosphate receptor Edg-1 agonist | S1PR1 | Phase 3 | Multiple Sclerosis (MS); Alzheimer Disease | Feb 2031 |
| Aptabio Therapeutics | Isuzinaxib Sphingosine-1-phosphate receptor 1 (S1PR1) modulator | S1PR1 | Phase 2 | Diabetic Kidney Disease (DKD) | Jun 2027 |
| Washington University School of Medicine | [C-11]-CS1P1 S1P1 PET imaging agent | S1PR1 | Phase 2 | Central Nervous System Cancer | Jun 2031 |
Lupus Erythematosus, Systemic (2) Alzheimer Disease (2) Relapsing Multiple Sclerosis (2) Colitis, Ulcerative (2) Ulcerative Colitis (2) Multiple Sclerosis (2) Nephritis, Lupus (1) Focal Segmental Glomerulosclerosis (1) Proteinuric Kidney Diseases (1) Moderate-to-severe Chronic Plaque Psoriasis (1) Ulcerative Colitis (UC) (1) Multiple Sclerosis (MS) (1)
small molecule (9), mixed (1)
Novartis (2) Viatris Innovation (1) Boehringer Ingelheim (1) Vanda Pharmaceuticals (1) Bristol-Myers Squibb (1) Washington University School of Medicine (1) Pfizer (1) Priothera SAS (1) Aptabio Therapeutics (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.